Briefly, our first proposal would be extracting naïve T lymphocytes and tumor cells from the patient, and co-cultivate them in the presence of cytokines to activate cytotoxic T-cell response: i.e., IL-2, INF-α and γ, and TNF-α. The gene discussed is TNF; the disease is neoplasm.